What does this research mean for the field?

Etentamig provides durable responses and a manageable safety profile, including only low-grade cytokine release syndrome without step-up dosing, in patients with relapsed/refractory multiple myeloma who have had prior exposure to BCMA-targeted therapies. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This trial aimed to assess the efficacy and safety of etentamig in patients with RRMM who were previously treated with BCMA-targeted therapies.

May 29, 2026

View Full Paper

Etentamig in patients (pts) with relapsed/refractory multiple myeloma (RRMM) with prior exposure to B-cell maturation antigen (BCMA)–targeted therapy.

SCS ChhabraMayo Clinic Hospital ESEmma SearleThe Christie NHS Foundation Trust RPRakesh PopatUniversity College London Hospitals NHS Foundation Trust

Key Points

This trial aimed to assess the efficacy and safety of etentamig in patients with RRMM who were previously treated with BCMA-targeted therapies.
Phase 1b MOVISO study (NCT05650632) evaluated etentamig in RRMM patients with ≥2 prior therapies including BCMA exposure.
Patients received etentamig 60 mg IV every 4 weeks, with primary endpoints including CRS and ICANS for safety, and ORR, DoR, and PFS for efficacy.
41 patients with previous BCMA exposure were treated, with detailed responses noted based on the last line of therapy.
Overall objective response rate was 47% (17/36), with better rates among patients whose last therapy was BCMA directed (58%).
Median duration of response was 13 months for patients overall, maintaining that duration for BCMA-directed prior therapy.
Median progression-free survival was 3.4 months overall, with a notable 9.4 months for patients whose last therapy was BCMA-directed.

Abstract

7508 Background: Data on response to BCMA-targeted therapies among BCMA-exposed pts with RRMM are limited. Outcomes after sequential/subsequent anti-BCMA bispecific T-cell engagers (Bs-TCE) are vital to evaluate. Etentamig is a next-generation differentiated BCMA x CD3 Bs-TCE composed of a bivalent BCMA-binding domain with a high-avidity, low-affinity CD3-binding domain potentially reducing cytokine release syndrome (CRS), and a silenced Fc tail for extended half-life and convenient monthly (Q4W) dosing. Phase 1 results of etentamig in RRMM showed robust efficacy and potential best-in-class safety. Methods: Arm B of the open-label, Phase 1b MOVISO study (NCT05650632) evaluated etentamig in pts with RRMM with ≥2 prior lines of therapy (PLT), including triple-class and prior BCMA exposure (antibody-drug conjugate ADC >30 days or CAR-T >6 months mo after last exposure). Primary safety endpoints were CRS and immune effector cell-associated neurotoxicity syndrome (ICANS); efficacy endpoints included objective response rate (ORR; IMWG 2016), duration of response (DoR), and progression-free survival (PFS). Pts received etentamig (60 mg IV; no step-up dosing SUD) on Cycle 1 Day 1 and Q4W thereafter. Results: At cutoff (June 11, 2025), 41 prior BCMA-exposed pts (CAR-T, n=24; ADC, n=17) had been treated; 24 (57%) were male, 38 (93%) were White, median (mdn) (range) age was 68 (43–89) years, 37 (88%) had ECOG PS ≤1, and 34 (81%) were triple-class refractory. Mdn (range) PLT was 6 (3–15). For 21 (51%) pts, the last PLT was BCMA directed; 23 (56%) had previously responded to anti-BCMA therapy (17/24 71% for CAR-T and 6/17 35% for ADC). Mdn (range) time from last prior CAR-T or ADC to first dose of etentamig was 15 (1–30) and 4 (1–45) mo, respectively. Mdn (range) follow-up was 5.5 (0.2–17.1) mo. Despite no SUD, CRS and ICANS were reported in 24 (57%) and 3 (7%) pts, respectively; all G1/2 events, except 1 G3 ICANS. G3/4 neutropenia and infections were reported in 15 (36%) and 17 (41%) pts, respectively. Efficacy outcomes are detailed in the Table (NE, not estimable). For pts whose last PLT was BCMA directed, MRD negativity (clonoSEQ, 10 –5 ) was seen in 2/3 (67%) evaluable pts, along with robust peak activation and proliferation of CD8+ T cells. Conclusions: Pts treated with etentamig achieved durable responses; rates were higher in pts who received CAR-T as last line. No new safety signals were observed; only low-grade CRS was seen despite no SUD. Clinical trial information: NCT05650632 . All prior BCMA (N=41) Prior BCMA CAR-T (N=24) ORR, n/n (%) 95% CI Overall 17/36 (47) 30–65 11/22 (50) 28–72 BCMA-directed last PLT 11/19 (58) 34–80 7/11 (64) 31–89 Mdn DoR, mo 95% CI, No. of pts Overall 13 7–NE, N=17 13 7–NE, N=11 BCMA-directed last PLT 13 7–NE, N=11 13 7–NE, N=7 Mdn PFS, mo 95% CI, No. of pts Overall 3.4 3–11, N=41 8.3 2–NE, N=24 BCMA-directed last PLT 9.4 2–NE, N=21 9.4 2–NE, N=12

KI fragen

Bookmark

View Full Paper

KI fragen

Bookmark

View Full Paper

Etentamig in patients (pts) with relapsed/refractory multiple myeloma (RRMM) with prior exposure to B-cell maturation antigen (BCMA)–targeted therapy.

Key Points

Abstract

Cite This Study

Also Consider

Also Consider